Antibacterial Agents TRIZ Cases

Removing the RHS secondary amine and using a 1,4-substituted piperidine linker preserves antibacterial activity while lowering hERG risk.

A mixed free and lipid-encapsulated inhaled antiinfective delivers immediate killing plus sustained lung exposure to limit rapid absorption and resistance.

Acid-labile nanoparticles disrupt bacterial adhesion on medical devices, preventing resistant biofilm formation without toxic antimicrobials.

Propylene glycol in water stabilizes dalbavancin injection, avoiding reconstitution while keeping impurities low at elevated temperatures.

1-Aminosulfonyl-2-carboxypyrrole inhibitors block metallo-beta-lactamases, restoring carbapenem efficacy against resistant Gram-negative bacteria.

Replacing unstable dichloropyrimidine with 4-chloro-6-methoxypyrimidine lifts sulfamonomethoxine yield above 91.5% and simplifies purification.

VHH antibodies bind ETEC adhesin proteins to block intestinal attachment and reduce diarrhea without relying on antibiotics.

A lignin-glucomannan supramolecular carrier forms a 3D hydrogen-bonded network that prevents phase separation in oral PDT formulations.

Modular 13-membered azaketolides vary ring substituents to improve Gram-negative antibacterial activity while simplifying macrolide synthesis.

Purified bacterial strains restore the gut microbiome to prevent C. difficile recurrence without donor-screening burdens of fecal transplantation.

A stepwise condensation, addition, cyclization, and acidification route raises sulfamerazine yield while lowering raw material cost and toxicity.

High-affinity N-terminal ADM binding stabilizes plasma ADM, preserves partial activity, and helps counter septic shock vasodilation.

Modular lipophosphonoxins selectively disrupt bacterial membranes to target resistant strains while lowering hemolysis and serum albumin binding.

Using Esc-COP-30 bacteriophage, this case shows selective lysis of pathogenic E. coli while reducing resistance pressure and sparing commensal bacteria.

Covalently linking antigen-binding moieties to mucin binders improves respiratory mucosal retention and counters clearance-driven efficacy loss.

A boron beta-lactamase inhibitor paired with oral ceftibuten restores activity against CRE and ESBL-producing gram-negative bacteria.

A sodium chloride and tea extract formulation boosts bioelectrical signaling through neural pathways to support tissue regeneration with less fibrosis.

A beta-lactamase inhibitor paired with meropenem restores activity against CRE in immunocompromised patients and helps reduce mortality.

Combining PD-1 binding with a second checkpoint target helps overcome tumor immune suppression and improve efficacy at lower concentrations.

Specific amino acid changes help alkaline phosphatase retain activity and stability in low-zinc conditions for inflammatory disease treatment.

A titanium-binding antimicrobial peptide coats dental implants to block biofilms without surface-damaging debridement.

An aqueous VHH-Fc antibody composition improves IL17A affinity while reducing aggregation, instability, and immunogenicity.

Sub-MIC keratinicyclin B and vancomycin work synergistically against C. difficile while sparing gut microbiota and reducing relapse.

Synergistic cannabinoid and antimicrobial combinations boost activity against resistant infections and biofilms while lowering dosage and side effects.